All News

Patients with BRAF mutations administered treatment with encorafenib/binimetinib trended toward improved and longer responses than patients who received dabrafenib/trametinib.

The new expanded approval was based on positive results from the phase 3 E1912 study.

Obesity increases the risk of developing type 2 diabetes by at least 6 times, regardless of genetic predisposition, according to a recent study.

The FDA has approved the first diagnostic test with a home collection option for the coronavirus disease 2019.

The new guidance authorizes licensed pharmacists to order and administer COVID-19 tests, including serology tests, that are approved by the FDA.

Today, we’re celebrating Hany Youssef, RPh, owner of LIFETIME Pharmacy in Allen, Texas.

A phase 3 trial evaluated nivolumab in combination with ipilimumab in patients with previously untreated MPM and successfully met its primary endpoint of overall survival.

Purdue University researchers have created technology that uses optical imaging to better help surgeons map out tumors in the body and understand how certain diseases affect activity in the brain.

Pharmacy Times® invites you to join us and experts in pharmacy to gain insight into the value pharmacists provide in treating patients throughout the pandemic.

Over the past 20 years, the specialty pharmacy channel has been the fastest growing segment of pharmacy practice.

More than 53% of survey respondents reported having a diversion event within the last year, in addition to 37% who were aware of at least 1 colleague who has diverted controlled substances.

Oncology/Hematology pharmacists from Boston Medical Center discuss how COVID-19 has affected their patients.

Today, we’re thanking Angela Garcia, PharmD, MPH, CPh, for her work as an American Pharmacists Association–Academy of Student Pharmacists (APhA-ASP) chapter advisor.

An overview of the most recent legal developments related to COVID-19 that are relevant to pharmacies.

This cohort included 307 patients with schizophrenia and 364 healthy controls who were 45 years old and younger.

The phase 3 trial evaluating nivolumab in combination with cabozantinib demonstrated positive results in the treatment of renal cell carcinoma (RCC).